{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:36:48Z","timestamp":1786725408818,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004169","name":"Meiji Seika Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004169","id-type":"DOI","asserted-by":"publisher"}]},{"name":"DongA-ST"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s12325-025-03290-9","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T10:47:39Z","timestamp":1753699659000},"page":"4681-4695","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetic Bioequivalence, Safety, and Immunogenicity of DMB-3115, an Ustekinumab Biosimilar, and EU- and US-Stelara in Healthy Adult Participants: A Randomized, Double-Blind, Single-Dose Study"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8242-0812","authenticated-orcid":false,"given":"Jun","family":"Morita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainard","family":"Fuhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Koernicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thin Thin","family":"Mencarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Fushimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"3290_CR1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","volume":"20","author":"B Verstockt","year":"2023","unstructured":"Verstockt B, Salas A, Sands BE, et al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2023;20:433\u201346. https:\/\/doi.org\/10.1038\/s41575-023-00768-1.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3290_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.788940","volume":"12","author":"P Hu","year":"2021","unstructured":"Hu P, Wang M, Gao H, et al. The role of helper T\u00a0cells in psoriasis. Front Immunol. 2021;12: 788940. https:\/\/doi.org\/10.3389\/fimmu.2021.788940.","journal-title":"Front Immunol"},{"issue":"Suppl 1","key":"3290_CR3","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1002\/msc.1694","volume":"20","author":"GE Fragoulis","year":"2022","unstructured":"Fragoulis GE, Siebert S. The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis. Musculoskelet Care. 2022;20(Suppl 1):S12\u201321. https:\/\/doi.org\/10.1002\/msc.1694.","journal-title":"Musculoskelet Care"},{"key":"3290_CR4","unstructured":"European Medicines Agency. Stelara (ustekinumab). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/stelara. Accessed 31 Jan 2025."},{"key":"3290_CR5","unstructured":"Janssen Pharmaceutical Companies. STELARA\u00ae (ustekinumab). Highlights of prescribing Information. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/STELARA-pi.pdf. Accessed 31 Jan 2025."},{"key":"3290_CR6","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(08)60725-4.","journal-title":"Lancet"},{"key":"3290_CR7","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(08)60726-6.","journal-title":"Lancet"},{"key":"3290_CR8","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1\u00a0year results of the phase\u00a03, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382:780\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(13)60594-2.","journal-title":"Lancet"},{"key":"3290_CR9","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375:1946\u201360. https:\/\/doi.org\/10.1056\/NEJMoa1602773.","journal-title":"N Engl J Med"},{"key":"3290_CR10","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201\u201314. https:\/\/doi.org\/10.1056\/NEJMoa1900750.","journal-title":"N Engl J Med"},{"key":"3290_CR11","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance-non-clinical-and-clinical-issues-revision-1_en.pdf. Accessed 18 Dec 2014."},{"key":"3290_CR12","unstructured":"United States Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/scientific-considerations-demonstrating-biosimilarity-reference-product. Accessed Apr 2015."},{"key":"3290_CR13","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical issues. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical-and-clinical-issues_en.pdf. Accessed 1 Dec 2012."},{"issue":"4","key":"3290_CR14","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1080\/13543784.2025.2500334","volume":"34","author":"J Ackroyd","year":"2025","unstructured":"Ackroyd J, Deodhar SS, Loganathan S, et al. Pharmacokinetic equivalence and comparative safety, tolerability, and immunogenicity of Biocon\u2019s ustekinumab (Bmab-1200) with EU-approved and US-licensed reference ustekinumab in healthy subjects: results from the Study to Test pharmacokinetic BioEquivalence of BiosimiLar ustekinumab to SteLARa (STELLAR-1). Expert Opin Investig Drugs. 2025;34(4):349\u201357. https:\/\/doi.org\/10.1080\/13543784.2025.2500334.","journal-title":"Expert Opin Investig Drugs"},{"issue":"12","key":"3290_CR15","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1002\/cpdd.1473","volume":"13","author":"S Balser","year":"2024","unstructured":"Balser S, Nopora K, K\u00f6rner J, Wedemeyer RS, Ansch\u00fctz M, Schug B. New ustekinumab biosimilar candidate FYB202: pharmacokinetic equivalence demonstrated in a randomized, double-blind, parallel-group, single-dose trial in healthy subjects. Clin Pharmacol Drug Dev. 2024;13(12):1308\u201316. https:\/\/doi.org\/10.1002\/cpdd.1473.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"3290_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.5414\/CP204492","volume":"62","author":"H Jeong","year":"2024","unstructured":"Jeong H, Kang T, Lee J, Im S. Comparison of SB17 and reference ustekinumab in healthy adults: a randomized, double-blind, single-dose, phase\u00a0I study. Int J Clin Pharmacol Ther. 2024;62(5):231\u201340. https:\/\/doi.org\/10.5414\/CP204492.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"10","key":"3290_CR17","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/cpdd.1305","volume":"12","author":"JN Hausfeld","year":"2023","unstructured":"Hausfeld JN, Challand R, McLendon K, et al. Pharmacokinetic profiles of a proposed biosimilar ustekinumab (BFI-751): results from a randomized phase\u00a01 trial. Clin Pharmacol Drug Dev. 2023;12(10):1001\u201312. https:\/\/doi.org\/10.1002\/cpdd.1305.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"9","key":"3290_CR18","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/cpdd.1301","volume":"12","author":"V Chow","year":"2023","unstructured":"Chow V, Mytych DT, Das S, Franklin J. Pharmacokinetic similarity of ABP 654, an ustekinumab biosimilar candidate: results from a randomized, double-blind study in healthy subjects. Clin Pharmacol Drug Dev. 2023;12(9):863\u201373. https:\/\/doi.org\/10.1002\/cpdd.1301.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"3290_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1080\/13543784.2023.2215426","volume":"32","author":"C Wynne","year":"2023","unstructured":"Wynne C, Hamilton P, McLendon K, et al. A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adults. Expert Opin Investig Drugs. 2023;32(5):417\u201327. https:\/\/doi.org\/10.1080\/13543784.2023.2215426.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"3290_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40259-022-00563-5","volume":"37","author":"M Wu","year":"2023","unstructured":"Wu M, Li X, Yang D, et al. Comparison of pharmacokinetic similarity, immunogenicity, and safety of ustekinumab and BAT2206 in healthy Chinese male subjects in a double-blind, randomized, single-dose, parallel-group Phase\u00a0I trial. BioDrugs. 2023;37(1):89\u201398. https:\/\/doi.org\/10.1007\/s40259-022-00563-5.","journal-title":"BioDrugs"},{"issue":"12","key":"3290_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.675358","volume":"18","author":"L Gao","year":"2021","unstructured":"Gao L, Li Q, Zhang H, et al. A biosimilarity study between QX001S and ustekinumab in healthy Chinese male subjects. Front Pharmacol. 2021;18(12):675358. https:\/\/doi.org\/10.3389\/fphar.2021.675358.","journal-title":"Front Pharmacol"},{"key":"3290_CR22","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40264-019-00797-3","volume":"42","author":"S Ghosh","year":"2019","unstructured":"Ghosh S, Gensler LS, Yang Z, et al. Ustekinumab safety in psoriasis, psoriatic arthritis, and Crohn\u2019s disease: an integrated analysis of phase\u00a0II\/III clinical development programs. Drug Saf. 2019;42:751\u201368. https:\/\/doi.org\/10.1007\/s40264-019-00797-3.","journal-title":"Drug Saf"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03290-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03290-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03290-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T09:04:04Z","timestamp":1756371844000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03290-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3290"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03290-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"2 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jun Morita, Hideki Fushimi, Naoki Cho are employees of Meiji Seika Pharma Co., Ltd., Rainard Fuhr, Thin Thin Mencarini and Thomas Koernicke have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, the International Council for Harmonisation Good Clinical Practice (ICH-GCP) guidelines, and the appropriate regulatory requirements in the countries in which the study was conducted. The protocol, its amendments, and informed consent documentation were reviewed and approved by the institutional review board at the site. All participants signed an institutional review board\/independent ethics committee-approved informed consent form before any study-specific procedures were performed. This trial is registered with the European Union Clinical Trials Register (EudraCT 2018-004033-33; date of registration, 17 October 2018).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}